Daily Market Updates: The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

S&P 5007,623.68▼0.5% Nasdaq25,955.34▼0.2% Dow52,215.16▼1.2% Russell 2K2,775.90▼0.3% 10-Yr4.99%+4bp VIX19.45+0.42 WTI$103.44▲4.0% Gold$4,010.00▼1.2% EUR/USD1.120▼0.3% BTC$79,744▼0.3% Nikkei62,908▼2.6%

At close · Sat, Oct 24, 2026

ETFs & Funds

Home›ETFs & Funds›Equity Funds›The excitement around Moderna’s cancer vaccine is cool…

The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

Reported · Written up by our desk · Equity Funds

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

← Newer storyAnthropic’s IPO filing shows explosive growth, risks and staggering c…Older story →Anthropic Makes IPO Filing Public, Plans Nasdaq Listing Under ‘ANT’

More like this

ETFs & FundsRetail investors are getting cold feet about stocks, just when the market needs them most

ETFs & FundsThe 5 big voting issues in the midterm elections that will impact your wallet

ETFs & FundsFrom Tokyo to Wall Street: Nomura’s Pedigree Powers Its U.S. ETF Push

ETFs & FundsMusk says SpaceX’s AI rivals are in trouble, sending their stocks lower

ETFs & FundsWith Consumer Staples in Rally Mode, Consider This Momentum ETF

Sources

MarketWatchThe excitement around Moderna’s cancer vaccine is cooling. Here’s why.

MarketWatchThe excitement around Moderna’s cancer vaccine is cooling. Here’s why.

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.